[54] D. Y. Logunov, et al., “Safety and efficacy of an rAd26 and rAd5 vector-based

heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised

controlled phase 3 trial in Russia,” Lancet, vol. 397, no. 10275, p. 671–681, 2021.

[55] H. Brussow, “COVID-19: Vaccination problems,” Environ. Microbiol., vol. 23, no.

6, pp. 2878–2890, 2021.

[56] J. H. Kim, F. Marks, and J. D. Clemens, “Looking beyond COVID-19 vaccine phase

3 trials,” Nat. Med., vol. 27, no. 2, pp. 205–211, 2021.

[57] H. Wang, et al., “Development of an inactivated vaccine candidate, BBIBP-CorV,

with potent protection against SARS-CoV-2,” Cell, vol. 182, no. 3, pp. 713–721 e9,

2020.

[58] Z. Wu, et al., “Safety, tolerability, and immunogenicity of an inactivated SARS-

CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a rando-

mised, double-blind, placebo-controlled, phase 1/2 clinical trial,” Lancet Infect.

Dis., vol. 21, no. 6, pp. 803–812, 2021.

[59] Y. Zhang, et al., “Safety, tolerability, and immunogenicity of an inactivated SARS-

CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind,

placebo-controlled, phase 1/2 clinical trial,” Lancet Infect. Dis., vol. 21, no. 2,

pp. 181–192, 2021.

[60] M. D. Tanriover, et al., “Efficacy and safety of an inactivated whole-virion SARS-

CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised,

placebo-controlled, phase 3 trial in Turkey,” Lancet, vol. 398, no. 10296,

pp. 213–222, 2021.

[61] R. L. Coffman, A. Sher, and R. A. Seder, “Vaccine adjuvants: Putting innate im-

munity to work,” Immunity, vol. 33, no. 4, pp. 492–503, 2010.

[62] R. Pati, M. Shevtsov, and A. Sonawane, “Nanoparticle vaccines against infectious

diseases,” Front Immunol, vol. 9, p. 2224, 2018.

[63] C. P. Karch and P. Burkhard, “Vaccine technologies: From whole organisms to ra-

tionally designed protein assemblies,” Biochem. Pharmacol., vol. 120, pp. 1–14, 2016.

[64] Y. Weisblum, et al., “Escape from neutralizing antibodies by SARS-CoV-2 spike

protein variants,”Elife, vol. , 9, p. e61312, 2020. doi: 10.7554/eLife.61312.

[65] V. Shinde, et al., “Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351

Variant,” N. Engl. J. Med., vol. 384, no. 20, pp. 1899–1909, 2021.

[66] C. Keech, et al., “Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein

nanoparticle vaccine,” N. Engl. J. Med., vol. 383, no. 24, pp. 2320–2332, 2020.

[67] P. T. Heath, et al., “Efficacy of the NVX-CoV2373 Covid-19 vaccine against the

B.1.1.7 variant,” N. Engl. J. Med., vol. 385, pp. 1172–1183, 2021. 10.1056/

NEJMoa2107659

[68] M. M. Silveira, G. Moreira, and M. Mendonca, “DNA vaccines against COVID-19:

Perspectives and challenges,” Life Sci., vol. 267, p. 118919, 2021.

314

Bioprocessing of Viral Vaccines